HIGHLIGHTS   |  March 21, 2020   FDA Accepts BLA for Proposed Biosimilar to Bevacizumab, MYL-1402O The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab. Read more   Identifying Patient Likelihood to Develop Cachexia Within Different Cancer Types This study examined both cachexia-inducing factors and patients with various cancers to better understand the disparity between cancer types and developing cachexia. Read more   In Case You Missed It

New Genetic Structural Variants Identified in Childhood Leukemias Previously unrecognized genetic structural variants in childhood leukemias could be used to evaluate the presence of minimal residual disease during chemotherapy and help to determine response to various therapies. Read more